When was Navignostics founded?

Navignostics was founded in 2022 and raised its 1st funding round within a year of its incorporation.

Where is Navignostics located?

Navignostics is headquartered in Zurich, Switzerland.

How many employees does Navignostics have?

As of Sep 30, 2026, the latest employee count at Navignostics is 17.

Is Navignostics a funded company?

Navignostics is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Sep 02, 2022.

When was the latest funding round of Navignostics?

Navignostics' latest funding was a $***** Seed round on Sep 02, 2022, with participation from 4 investors. Its primary sector is Oncology. In Switzerland, the Oncology sector has seen $106M in funding in 2026 to date.

Where does Navignostics rank among its competitors?

Navignostics ranks 140th amongst 428 active competitors, of which 142 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was 4baseCare, which secured an undisclosed amount in Jul, 2026.

Who are the top competitors of Navignostics?

Navignostics' top competitors include MedGenome, Geneoscopy and Personalis. Among them, 4baseCare secured the most recent funding round in July, 2026.

Navignostics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of personalized diagnostics for cancer patients. The company is developing diagnostic tests to develop treatments for several tumor indications. The company's products include novel spatial biomarker tests for patients with metastatic colorectal cancer.

Website: www.navignostics.com/
Email ID: *****@navignostics.com
Phone Number: +41 **********

Key Metrics

Founded Year

2022

Location

Zurich, Switzerland

Stage

Seed

Total Funding

$7.65M in 1 round

Latest Funding Round

Seed, Sep 02, 2022, $*****

Investors

Bruker & 3 more

Ranked

140^th among 428 active competitors

Employee Count

17 as on Sep 30, 2026

Similar Companies

Geneoscopy & 548 more

View Navignostics' full profile

Navignostics has raised a total funding of $7.65M over 1 round. Its latest funding round was a Seed round on Sep 02, 2022 for $*****. 4 investors participated in its latest round. Navignostics has 4 institutional investors.

Here is the list of recent funding rounds of Navignostics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 02, 2022	3454849	Seed	9812207	6325360	4830875	4410837

Access funding benchmarks and valuations. Sign up today!

View details of Navignostics's funding rounds and investors

The founders of Navignostics are Stephane Chevrier, Bernd Bodenmiller, Andrea Jacobs and Jana Fischer.

Here are the details of Navignostics' key team members:

Stephane Chevrier: Co-Founder of Navignostics.
Bernd Bodenmiller: Co-Founder of Navignostics.
Andrea Jacobs: Co-Founder, Coo of Navignostics.
Jana Fischer: Co-Founder of Navignostics.

View details of Navignostics's Founder profiles and Board Members

Navignostics' employee count trend

Navignostics has 17 employees as of Sep 26. Here is Navignostics's employee count trend over the years:

Uncover Navignostics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Navignostics include MedGenome, Geneoscopy and Personalis. Here is the list of Top 10 competitors of Navignostics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MedGenome 2013, Bengaluru (India), Series E	Provider of DNA sequencing, bioinformatics, and multiomics services	$264M	Novo Holdings, Peak XV Partners & 30 others	70/100
2nd	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	69/100
3rd	Personalis 2011, Menlo Park (United States), Acquired	Provider of genomic sequencing and diagnosis software for the healthcare industry	$87.3M	Abingworth, Lightspeed Venture Partners & 5 others	68/100
4th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of genome editing therapeutics using CRISPR and Cas9 technology	$85M	Atlas Venture, Novartis & 10 others	68/100
5th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	67/100
6th	4baseCare 2018, Bengaluru (India), Series B	Provider of precision oncology solutions, including genomic testing and digital health	$27.9M	Tremis Consultancy, Yali Capital & 41 others	67/100
7th	NeoGenomics 2002, Fort Myers (United States), Public	Provider of cancer genetic diagnostic services	-	Ranger Investments, Aspen Capital & 1 others	63/100
8th	Exosome Diagnostics 2008, Boston (United States), Acquired	Developer of blood-based cancer molecular diagnostics for patient stratification and disease monitoring	$119M	Forbion, NGN Capital & 7 others	62/100
9th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, True Ventures & 16 others	62/100
10th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Advent Life Sciences & 11 others	62/100
140th	Navignostics 2022, Zurich (Switzerland), Seed	Developer of personalized diagnostics for cancer patients	$7.65M	Think.Health, Bruker & 2 others	38/100